Get the Stockscreener App
13.52
6.76%
-0.98
After Hours:
14.00
0.48
+3.55%
Mbx Biosciences Inc stock is traded at $13.52, with a volume of 1.61M.
It is down -6.76% in the last 24 hours and up +24.84% over the past month.
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.
See More
Previous Close:
$14.50
Open:
$14.25
24h Volume:
1.61M
Relative Volume:
1.43
Market Cap:
$454.19M
Revenue:
-
Net Income/Loss:
$-47.20M
P/E Ratio:
-8.6373
EPS:
-1.5653
Net Cash Flow:
$-43.65M
1W Performance:
-14.43%
1M Performance:
+24.84%
6M Performance:
+81.97%
1Y Performance:
-42.59%
1-Day Range:
$13.43
$14.44
1-Week Range:
$13.43
$16.52
52-Week Range:
$4.8069
$27.50
Mbx Biosciences Inc Stock (MBX) Company Profile
Name
Mbx Biosciences Inc
Sector
Industry
Phone
(317) 989-3100
Address
11711 N. MERIDIAN STREET, CARMEL
Compare MBX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
13.52 | 648.37M | 0 | -47.20M | -43.65M | -1.5653 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Resumed | Jefferies | Buy |
| Aug-05-25 | Initiated | Mizuho | Outperform |
| Jul-16-25 | Initiated | Oppenheimer | Outperform |
| Apr-10-25 | Initiated | Citizens JMP | Mkt Outperform |
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | JP Morgan | Overweight |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Stifel | Buy |
View All
Mbx Biosciences Inc Stock (MBX) Latest News
Truist Securities initiates MBX Biosciences stock with Buy rating, $50 target - Investing.com UK
Predicting MBX Biosciences Inc. trend using moving averagesWeekly Trend Summary & High Accuracy Trade Signal Alerts - newser.com
Trend analysis for MBX Biosciences Inc. this weekQuarterly Portfolio Report & Long-Term Investment Growth Plans - newser.com
Is MBX Biosciences Inc. forming a bottoming baseM&A Rumor & Pattern Based Trade Signal System - newser.com
Detecting price anomalies in MBX Biosciences Inc. with AIJuly 2025 Market Mood & Target Return Focused Picks - newser.com
Is MBX Biosciences Inc. stock a defensive play in 2025Market Sentiment Summary & Daily Price Action Insights - newser.com
Can MBX Biosciences Inc. hit a new high this monthWall Street Watch & Fast Gaining Stock Strategy Reports - newser.com
What to expect from MBX Biosciences Inc. in the next 30 days2025 Growth vs Value & AI Powered Market Entry Strategies - newser.com
What sentiment indicators say about MBX Biosciences Inc. stock2025 Earnings Impact & Free Long-Term Investment Growth Plans - newser.com
MBX Biosciences (NASDAQ:MBX) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
How MBX Biosciences Inc. stock compares to market leaders2025 Trading Recap & Low Risk High Reward Ideas - newser.com
Wellington Management Group LLP Increases Stake in MBX Biosciences Inc - GuruFocus
Wall Street Analysts See a 280.14% Upside in MBX Biosciences, Inc. (MBX): Can the Stock Really Move This High? - sharewise.com
Advanced analytics toolkit walkthrough for MBX Biosciences Inc.Bull Run & Weekly High Potential Stock Alerts - newser.com
Combining price and volume data for MBX Biosciences Inc.2025 Key Lessons & Consistent Growth Equity Picks - newser.com
Applying Elliott Wave Theory to MBX Biosciences Inc.Portfolio Performance Report & Entry Point Confirmation Signals - newser.com
MBX Biosciences stock down on pricing upsized public offering at $18.00 per share - MSN
MBX Biosciences stock rating reiterated at Market Outperform by Citizens - Investing.com
Insiders Snap Up $54M in Biotech and Offshore Driller Stocks - 24/7 Wall St.
Guggenheim Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $84 - 富途牛牛
Using AI based signals to follow MBX Biosciences Inc.Trade Entry Report & Weekly Chart Analysis and Guides - newser.com
Developing predictive dashboards with MBX Biosciences Inc. dataWeekly Stock Analysis & Low Risk Growth Stock Ideas - newser.com
MBX Biosciences Inc. stock momentum explainedPortfolio Gains Summary & Growth Focused Entry Point Reports - newser.com
Is it too late to sell MBX Biosciences Inc.Bear Alert & AI Powered Buy and Sell Recommendations - newser.com
How MBX Biosciences Inc. stock reacts to bond yieldsM&A Rumor & Short-Term High Return Strategies - newser.com
Will MBX Biosciences Inc. bounce back from current support2025 Key Highlights & Capital Protection Trading Alerts - newser.com
MBX Biosciences Inc Stock Analysis and ForecastEconomic Impact on Stocks & Learn to Think Like a Long-Term Investor - earlytimes.in
Using Bollinger Bands to evaluate MBX Biosciences Inc.Gold Moves & AI Enhanced Trading Signals - newser.com
Analyzing MBX Biosciences Inc. with multi timeframe chartsDividend Hike & Weekly Momentum Picks - newser.com
Mbx Biosciences Inc Stock (MBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.15%
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):